Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Mizuho on uniQure BV (QURE): 'expressed confidence the overall signal — namely the slowing of disease progression — should remain directionally consistent'

June 17, 2026 1:27 PM EDT

Mizuho analyst Uy Ear reiterated an Outperform rating and $35.00 price target on uniQure BV (NASDAQ: QURE).

The analyst comments "FDA Under New Leadership Seems to Signal Renewed Flexibility in Rare Diseases: Regarding the Type B meeting, management noted the core review team remained largely unchanged, but leadership-level discussions seem to have enabled a more pragmatic path forward, which led to the agency's willingness to find the 3-year Phase I/II results as supportive of an Accelerated BLA filing and non-sham control confirmatory Phase 3 trial. Management highlighted a constructive shift in tone following recent... More